Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
267 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cystic Fibrosis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Cystic Fibrosis - Pipeline Review, H1 2015', provides an overview of the Cystic Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cystic Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cystic Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Cystic Fibrosis Overview 11 Therapeutics Development 12 Pipeline Products for Cystic Fibrosis - Overview 12 Pipeline Products for Cystic Fibrosis - Comparative Analysis 13 Cystic Fibrosis - Therapeutics under Development by Companies 14 Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes 20 Cystic Fibrosis - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Cystic Fibrosis - Products under Development by Companies 26 Cystic Fibrosis - Products under Investigation by Universities/Institutes 32 Cystic Fibrosis - Companies Involved in Therapeutics Development 33 Actelion Ltd 33 Alaxia SAS 34 AlgiPharma AS 35 Arcturus Therapeutics, Inc 36 Bayer AG 37 Beech Tree Labs, Inc. 38 Carolus Therapeutics, Inc. 39 Celsus Therapeutics Plc 40 Celtaxsys, Inc. 41 Chiesi Farmaceutici SpA 42 Cilian AG 43 Concert Pharmaceuticals, Inc. 44 Corbus pharmaceuticals, Inc. 45 Cubist Pharmaceuticals, Inc. 46 DiscoveryBiomed, Inc. 47 Errant Gene Therapeutics, LLC 48 Galapagos NV 49 GlaxoSmithKline plc 50 Grifols, S.A. 51 Invion Limited 52 InvivoGen Therapeutics 53 JHL Biotech, Inc. 54 Kamada Ltd. 55 Lamellar Biomedical Ltd 56 Laurent Pharmaceuticals Inc. 57 Microbion Corporation 58 Mucokinetica Ltd. 59 N30 Pharmaceuticals 60 NanoBio Corporation 61 Nostrum Pharmaceuticals, LLC 62 Novabiotics Ltd 63 Novartis AG 64 Ockham Biotech Limited 65 OSE Pharma SA 66 Parion Sciences, Inc. 67 Pfizer Inc. 68 Pharmaxis Limited 69 Polyphor Ltd. 70 Progenra, Inc. 71 ProQR Therapeutics N.V. 72 Protalix BioTherapeutics, Inc. 73 PTC Therapeutics, Inc. 74 Pulmatrix, Inc. 75 Reata Pharmaceuticals, Inc. 76 ReveraGen BioPharma, Inc. 77 Serendex Pharmaceuticals A/S 78 Shire Plc 79 Synovo GmbH 80 Verona Pharma Plc 81 Vertex Pharmaceuticals Incorporated 82 Xenetic Biosciences plc 83 Cystic Fibrosis - Therapeutics Assessment 84 Assessment by Monotherapy Products 84 Assessment by Combination Products 85 Assessment by Target 86 Assessment by Mechanism of Action 89 Assessment by Route of Administration 92 Assessment by Molecule Type 94 Drug Profiles 96 (fosfomycin + tobramycin) - Drug Profile 96 alpha-1 proteinase inhibitor (human) second generation - Drug Profile 97 ALX-009 - Drug Profile 100 Anti-Microbial Drug for Cystic Fibrosis - Drug Profile 101 ataluren - Drug Profile 102 BTL-na - Drug Profile 105 CFX-1 - Drug Profile 106 CSY-0073 - Drug Profile 107 CT-2009 - Drug Profile 108 CTX-4430 - Drug Profile 109 cysteamine - Drug Profile 110 D-Ivacaftor - Drug Profile 112 dapsone - Drug Profile 113 Deoxyribonuclease II to Inhibit DNA Synthesis for Cystic Fibrosis - Drug Profile 114 dornase alfa biosimilar - Drug Profile 115 Drug for Cystic Fibrosis - Drug Profile 116 Drug to Activate Kir 4.2 for Cystic Fibrosis - Drug Profile 117 Drugs for COPD and Cystic Fibrosis - Drug Profile 118 Drugs for Cystic Fibrosis Lung Infections - Drug Profile 119 EBX-001 - Drug Profile 120 FDL-169 - Drug Profile 121 fenretinide - Drug Profile 122 fosfomycin - Drug Profile 123 Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile 124 Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile 125 GLPG-1837 - Drug Profile 126 GSK-2225745 - Drug Profile 128 Heparin - Drug Profile 129 JBT-101 - Drug Profile 130 levofloxacin - Drug Profile 131 LMS-611 - Drug Profile 132 lumacaftor - Drug Profile 133 LUNAR-CF - Drug Profile 136 mannitol - Drug Profile 137 miglustat - Drug Profile 140 MKA-104 - Drug Profile 142 molgramostim - Drug Profile 143 N-1785 - Drug Profile 145 N-1861 - Drug Profile 146 N-6022 - Drug Profile 147 N-91115 - Drug Profile 148 N-91138 - Drug Profile 149 N-91169 - Drug Profile 150 nadolol - Drug Profile 151 NB-401 - Drug Profile 153 Next Generation Correctors - Drug Profile 154 nitric oxide - Drug Profile 155 nitric oxide - Drug Profile 156 Oligomer G for Cystic Fibrosis - Drug Profile 157 Oligonucleotide to Activate CFTR for Cystic Fibrosis - Drug Profile 159 ORP-100 - Drug Profile 160 P-1037 - Drug Profile 161 Peptide to Block ENaC for Cystic Fibrosis and Hypertension - Drug Profile 162 POL-6014 - Drug Profile 163 PRX-110 - Drug Profile 165 pseudomonas aeruginosa vaccine - Drug Profile 166 PulmoXen - Drug Profile 167 PUR-118 - Drug Profile 168 PUR-1900 - Drug Profile 169 PUR-2000 - Drug Profile 170 PXS-4728A - Drug Profile 171 QBW-251 - Drug Profile 172 QR-010 - Drug Profile 173 Recombinant A1PI - Drug Profile 174 Recombinant Enzyme for Cystic Fibrosis - Drug Profile 176 Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Drug Profile 177 Recombinant Human Follistatin - Drug Profile 178 Recombinant Protein for Infectious Diseases and Respiratory Disorders - Drug Profile 179 riociguat - Drug Profile 180 RPL-554 - Drug Profile 182 Small Molecule for Cystic Fibrosis - Drug Profile 185 Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis - Drug Profile 186 Small Molecule to Activate CFTR Protein for Cystic Fibrosis - Drug Profile 187 Small Molecule to Activate Nrf2 for Cystic Fibrosis - Drug Profile 188 Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 189 Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD - Drug Profile 190 Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis - Drug Profile 191 Small Molecules for Cystic Fibrosis - Drug Profile 192 Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile 193 Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile 194 Small Molecules to Agonize PPAR-Gamma for COPD and Cystic Fibrosis - Drug Profile 195 Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 196 Small Molecules to Inhibit USP8 for Cystic Fibrosis - Drug Profile 197 solithromycin - Drug Profile 198 SP-14 - Drug Profile 200 SP-9 - Drug Profile 201 tritoqualine - Drug Profile 202 VBP-15 - Drug Profile 203 VRT-325 - Drug Profile 205 VX-661 - Drug Profile 206 Cystic Fibrosis - Recent Pipeline Updates 207 Cystic Fibrosis - Dormant Projects 246 Cystic Fibrosis - Discontinued Products 252 Cystic Fibrosis - Product Development Milestones 253 Featured News & Press Releases 253 Appendix 260 Methodology 260 Coverage 260 Secondary Research 260 Primary Research 260 Expert Panel Validation 260 Contact Us 260 Disclaimer 261
List of Tables Number of Products under Development for Cystic Fibrosis, H1 2015 18 Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H1 2015 19 Number of Products under Development by Companies, H1 2015 21 Number of Products under Development by Companies, H1 2015 (Contd..1) 22 Number of Products under Development by Companies, H1 2015 (Contd..2) 23 Number of Products under Development by Companies, H1 2015 (Contd..3) 24 Number of Products under Development by Companies, H1 2015 (Contd..4) 25 Number of Products under Investigation by Universities/Institutes, H1 2015 27 Comparative Analysis by Late Stage Development, H1 2015 28 Comparative Analysis by Clinical Stage Development, H1 2015 29 Comparative Analysis by Early Stage Development, H1 2015 30 Comparative Analysis by Unknown Stage Development, H1 2015 31 Products under Development by Companies, H1 2015 32 Products under Development by Companies, H1 2015 (Contd..1) 33 Products under Development by Companies, H1 2015 (Contd..2) 34 Products under Development by Companies, H1 2015 (Contd..3) 35 Products under Development by Companies, H1 2015 (Contd..4) 36 Products under Development by Companies, H1 2015 (Contd..5) 37 Products under Investigation by Universities/Institutes, H1 2015 38 Cystic Fibrosis - Pipeline by Actelion Ltd, H1 2015 39 Cystic Fibrosis - Pipeline by Alaxia SAS, H1 2015 40 Cystic Fibrosis - Pipeline by AlgiPharma AS, H1 2015 41 Cystic Fibrosis - Pipeline by Arcturus Therapeutics, Inc, H1 2015 42 Cystic Fibrosis - Pipeline by Bayer AG, H1 2015 43 Cystic Fibrosis - Pipeline by Beech Tree Labs, Inc., H1 2015 44 Cystic Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2015 45 Cystic Fibrosis - Pipeline by Celsus Therapeutics Plc, H1 2015 46 Cystic Fibrosis - Pipeline by Celtaxsys, Inc., H1 2015 47 Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H1 2015 48 Cystic Fibrosis - Pipeline by Cilian AG, H1 2015 49 Cystic Fibrosis - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 50 Cystic Fibrosis - Pipeline by Corbus pharmaceuticals, Inc., H1 2015 51 Cystic Fibrosis - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 52 Cystic Fibrosis - Pipeline by DiscoveryBiomed, Inc., H1 2015 53 Cystic Fibrosis - Pipeline by Errant Gene Therapeutics, LLC, H1 2015 54 Cystic Fibrosis - Pipeline by Galapagos NV, H1 2015 55 Cystic Fibrosis - Pipeline by GlaxoSmithKline plc, H1 2015 56 Cystic Fibrosis - Pipeline by Grifols, S.A., H1 2015 57 Cystic Fibrosis - Pipeline by Invion Limited, H1 2015 58 Cystic Fibrosis - Pipeline by InvivoGen Therapeutics, H1 2015 59 Cystic Fibrosis - Pipeline by JHL Biotech, Inc., H1 2015 60 Cystic Fibrosis - Pipeline by Kamada Ltd., H1 2015 61 Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H1 2015 62 Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc., H1 2015 63 Cystic Fibrosis - Pipeline by Microbion Corporation, H1 2015 64 Cystic Fibrosis - Pipeline by Mucokinetica Ltd., H1 2015 65 Cystic Fibrosis - Pipeline by N30 Pharmaceuticals, H1 2015 66 Cystic Fibrosis - Pipeline by NanoBio Corporation, H1 2015 67 Cystic Fibrosis - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2015 68 Cystic Fibrosis - Pipeline by Novabiotics Ltd, H1 2015 69 Cystic Fibrosis - Pipeline by Novartis AG, H1 2015 70 Cystic Fibrosis - Pipeline by Ockham Biotech Limited, H1 2015 71 Cystic Fibrosis - Pipeline by OSE Pharma SA, H1 2015 72 Cystic Fibrosis - Pipeline by Parion Sciences, Inc., H1 2015 73 Cystic Fibrosis - Pipeline by Pfizer Inc., H1 2015 74 Cystic Fibrosis - Pipeline by Pharmaxis Limited, H1 2015 75 Cystic Fibrosis - Pipeline by Polyphor Ltd., H1 2015 76 Cystic Fibrosis - Pipeline by Progenra, Inc., H1 2015 77 Cystic Fibrosis - Pipeline by ProQR Therapeutics N.V., H1 2015 78 Cystic Fibrosis - Pipeline by Protalix BioTherapeutics, Inc., H1 2015 79 Cystic Fibrosis - Pipeline by PTC Therapeutics, Inc., H1 2015 80 Cystic Fibrosis - Pipeline by Pulmatrix, Inc., H1 2015 81 Cystic Fibrosis - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 82 Cystic Fibrosis - Pipeline by ReveraGen BioPharma, Inc., H1 2015 83 Cystic Fibrosis - Pipeline by Serendex Pharmaceuticals A/S, H1 2015 84 Cystic Fibrosis - Pipeline by Shire Plc, H1 2015 85 Cystic Fibrosis - Pipeline by Synovo GmbH, H1 2015 86 Cystic Fibrosis - Pipeline by Verona Pharma Plc, H1 2015 87 Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 88 Cystic Fibrosis - Pipeline by Xenetic Biosciences plc, H1 2015 89 Assessment by Monotherapy Products, H1 2015 90 Assessment by Combination Products, H1 2015 91 Number of Products by Stage and Target, H1 2015 93 Number of Products by Stage and Mechanism of Action, H1 2015 96 Number of Products by Stage and Route of Administration, H1 2015 99 Number of Products by Stage and Molecule Type, H1 2015 101 Cystic Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015 213 Cystic Fibrosis - Dormant Projects, H1 2015 252 Cystic Fibrosis - Dormant Projects (Contd..1), H1 2015 253 Cystic Fibrosis - Dormant Projects (Contd..2), H1 2015 254 Cystic Fibrosis - Dormant Projects (Contd..3), H1 2015 255 Cystic Fibrosis - Dormant Projects (Contd..4), H1 2015 256 Cystic Fibrosis - Dormant Projects (Contd..5), H1 2015 257 Cystic Fibrosis - Discontinued Products, H1 2015 258
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
